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ABSTRACT

Streptococcus pyogenes (group A streptococcus; GAS) is an important human
pathogen that colonizes epithelial and mucosal surfaces. Group A streptococcal
disease can be relatively minor, such as streptococcal pharyngitis, or severe and lifethreatening, such as necrotizing fasciitis. There has been a resurgence of severe
infection with GAS since the mid-1980s that has been paralleled be the emergence of
a globally disseminated clone, M1T1. The M1T1 clone of GAS presents as the most
common cause of streptococcal pharyngitis in developed countries and are also
overrepresented in cases of severe infection.

Most invasive bacterial infections are caused by species that more commonly
colonize the human host with minimal or no symptoms. Although phenotypic or
genetic correlates underlying a bacterium’s shift to enhanced virulence potential have
been studied, the in vivo selection pressures governing such shifts are poorly
understood. The globally disseminated M1T1 clone of GAS is linked with the rare
but life-threatening syndromes of necrotizing fasciitis and toxic shock syndrome.
Mutations in the group A streptococcal control of virulence regulatory sensor kinase
(covR/S) operon are associated with severe invasive disease, abolishing expression of
a broad spectrum cysteine protease (SpeB) and allowing the recruitment and
activation of host plasminogen on the bacterial surface. This study describes how a
bacteriophage-encoded group A streptococcal DNase (Sda1), which facilitates the
pathogen’s escape from neutrophil extracellular traps (NETs), can serve as a
selective force for covR/S mutation. The results provide a paradigm whereby
horizontal gene transfer and natural selection exerted by the innate immune system
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generate hypervirulent bacterial variants with increased risk of systemic
dissemination.

This study sought to investigate if there was a cost of fitness associated with covR/S
mutation that counterbalances the dramatic increase in virulence. It was found that
covR/S mutant bacteria had reduced capacity to bind fibronectin and collagen, both
components of the extracellular matrix bound by streptococcal adhesins. The covR/S
mutant strain examined in this study also showed reduced capacity to bind to
epithelial cell layers as a consequence of increased capsule expression. This mutant
strain displayed reduced capacity to form biofilms. An animal model of skin
colonization was used to show that the covR/S mutant strain has a colonization
defect. This reduced capacity to colonize presents an explanation as to why
hypervirulent covR/S mutant M1T1 group A streptococci are not rapidly spread
amongst the community.

The role of SpeB in the course of infection is still unclear. This study utilized a
SpeB-negative M1T1 clinical isolate, 5628, with a naturally occurring mutation in
the gene encoding the regulator RopB, to elucidate the role of RopB and SpeB in
systemic virulence. Allelic exchange mutagenesis was used to replace the mutated
ropB allele in 5628 with the intact allele from the well characterized isolate 5448.
The inverse allelic exchange was also performed to replace the intact ropB in 5448
with the mutated allele from 5628. An intact ropB was found to be essential for SpeB
expression. While the ropB mutation was shown to have no effect on haemolysis of
RBCs, extracellular DNase activity or survival in the presence of neutrophils, strains
with the mutated ropB allele were less virulent in murine systemic models of
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infection. An isogenic SpeB knockout strain containing an intact RopB showed
similarly reduced virulence. Microarray analysis found genes of the SpeB operon to
be the primary target of RopB regulation. These data show that an intact RopB and
efficient SpeB production are necessary for systemic infection with GAS.
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